Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01484522
Other study ID # IMPAACT P1089
Secondary ID U01AI068632
Status Completed
Phase N/A
First received September 29, 2011
Last updated November 30, 2011
Start date October 2009
Est. completion date September 2010

Study information

Verified date November 2011
Source International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Observational

Clinical Trial Summary

The purpose of this research study is to evaluate the immune response to the H1N1 influenza or "flu" vaccine. The "immune response" is how your body recognizes and defends itself against bacteria, viruses, and substances that may be harmful to the body.

HIV-1 infected children typically respond more poorly to vaccines compared to uninfected, healthy children and so this study hopes to learn whether or not the body will successfully produce enough antibodies (proteins that fight infection) that will prevent or fight the H1N1 flu virus. There is no information yet on the safety or immune response to this vaccine in children infected with HIV.


Description:

HIV-infected children typically respond poorer to vaccines as compared to normal children. The FDA has currently approved several Influenza A 2009 monovalent vaccines to be used in children and adults. However, little data is available in perinatally infected youth. Therefore, knowledge of the immunogenicity of several of the licensed Influenza A 2009 monovalent vaccines in HIV-infected children and youth is critically important to address the health care needs of this vulnerable population. Efforts are currently underway to evaluate Influenza A 2009 monovalent vaccines in healthy children as well as other populations. This study will assess the immune response following receipt of three Influenza A monovalent vaccines in HIV-1 infected children and youth. Protection of HIV-1 infected children and youth from 2009 H1N1 Influenza A will require knowledge of immunogenicity of these new products in this population. The 2009 (H1N1) Influenza A virus is likely to infect a significant proportion of HIV-1 infected children and youth. Immunogenicity of licensed and commercially available Influenza A 2009 monovalent vaccines must be established in HIV-1 infected children in order to assure that this population is protected. Lack of a protective immune response would support the need for additional measures to protect this high risk population.


Recruitment information / eligibility

Status Completed
Enrollment 149
Est. completion date September 2010
Est. primary completion date January 2010
Accepts healthy volunteers No
Gender Both
Age group 6 Months to 25 Years
Eligibility Inclusion Criteria:

1. Children and youth 6 months to <25 years of age at study entry.

2. HIV infection, defined as positive test results obtained from 2 different samples. Tests may include two of the same type OR two different types of tests listed below, as long as there are positive test results obtained from 2 different samples:

- HIV-1 antibody (ELISA + WB), obtained at age >18 months

- HIV-1 culture, any age

- HIV-1 DNA PCR, any age

- HIV-1 RNA PCR >10,000 copies/mL, any age

- Neutralizable HIV-1 p24 antigen obtained >28 days of age

3. In the opinion of the investigator, the route of HIV-1 transmission is perinatally acquired.

4. Parent or legal guardian, youth of legal age, or subjects who are emancipated minors, who are willing and able to provide signed informed consent.

5. Planned receipt of one of the following FDA licensed Influenza A (H1N1) 2009 Monovalent Vaccines within 24 hours following study entry:

- Group A: Influenza A (H1N1) 2009 Monovalent Vaccine (MedImmune FluMist®)

- Group B: Influenza A (H1N1) 2009 Monovalent Vaccine (Novartis Fluvirin®)

- Group C: Influenza A (H1N1) 2009 Monovalent Vaccine (Sanofi Pasteur Fluzone®) *OR has received one of the above vaccines within 4 hours prior to study entry.

Exclusion Criteria:

1. Has a history of probable or proven pandemic 2009 H1N1 Influenza A virus infection prior to study entry.

2. Has received seasonal FluMist vaccine within 2 weeks prior to study entry.

3. Has received any 2009 H1N1 vaccines prior to the day of entry.

4. Has received any immunoglobulin or blood products within 3 months prior to study entry.

5. Has any condition that would, in the opinion of the site investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the study.

6. Use of anti-cancer chemotherapy or radiation therapy within the 36 months preceding study entry, or has immunosuppression as a result of an underlying illness or treatment (other than HIV-1 infection).

7. Has an active neoplastic disease.

8. Long term use of glucocorticoids, including oral or parenteral prednisone or equivalent (more than or equal to 2 mg/kg per day or more than or equal to 20 mg total dose) for more than 2 weeks in the past 6 months, or high-dose inhaled steroids (>800 mcg/day of beclomethasone dipropionate or equivalent) within the preceding 6 months (nasal and topical steroids are allowed).

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Biological:
FluMist
Administered at the manufacture's recommended dose
Fluvirin
Vaccine administered at the manufacturer's recommended dose.
Fluzone
Vaccine administered at manufacturer's recommended dose

Locations

Country Name City State
Puerto Rico University of Puerto Rico Pediatric HIV/AIDS Research (6601) San Juan
United States University of Colorado Denver NICHD CRS (5052) Aurora Colorado
United States Univ. of Alabama Birmingham NICHD CRS (5096) Birmingham Alabama
United States Children's Hospital of Boston NICHD CRS (5009) Boston Massachusetts
United States Jacobi Medical Center Bronx (5013) Bronx New York
United States Chicago Children's CRS (4001) Chicago Illinois
United States Wayne State University/Children's Hospital of Michigan NICHD CRS Detroit Michigan
United States USC/Los Angeles County Medical Center NICHD CRS Los Angeles California
United States St. Jude/UTHSC CRS (6501) Memphis Tennessee
United States University of Miami Pediatric/Perinatal HIV/AIDS (4201) Miami Florida
United States New York University NY (5012) New York New York
United States NJ Med School CRS (2802) Newark New Jersey
United States The Children's Hospital of Philadelphia (6701) Philadelphia Pennsylvania
United States University of California San Francisco NICHD CRS (5091) San Francisco California
United States SUNY Stony Brook (5040) Stony Brook New York
United States University of South Florida Tampa (5018) Tampa Florida
United States WNE Maternal Pediatric Adolescent AIDS CRS Worcester Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
International Maternal Pediatric Adolescent AIDS Clinical Trials Group National Institute of Allergy and Infectious Diseases (NIAID)

Countries where clinical trial is conducted

United States,  Puerto Rico, 

Outcome

Type Measure Description Time frame Safety issue
Primary The short term immune response following immunization with a licensed Influenza A (H1N1) 2009 Monovalent Vaccine administered as a single dose in perinatally HIV-1 infected children and youth aged >10 to <25 years. 8 months No
Primary The short term immune response following second immunization with a licensed Influenza A (H1N1) 2009 Monovalent Vaccine in perinatally HIV-1 infected children > 6 months to < 10 years of age. 8 months No
Secondary The immune response following first immunization with a licensed Influenza A (H1N1) 2009 monovalent vaccine in children aged > 6 months to < 10 years of age. 8 months No
Secondary Persistence of antibody responses 7 months after receipt of the first immunization with a licensed Influenza A (H1N1) 2009 monovalent vaccine. 8 months No
Secondary Immune responses with CD4+ cell count and timing of seasonal trivalent influenza vaccine (TIV). 8 months No
Secondary Immune responses with CD4 percent and timing of seasonal trivalent influenza vaccine (TIV). 8 months No
Secondary Immune responses with ARV use and timing of seasonal trivalent influenza vaccine (TIV). 8 months No
Secondary Immune responses with plasma HIV-1 RNA concentration and timing of seasonal trivalent influenza vaccine (TIV). 8 months No
See also
  Status Clinical Trial Phase
Completed NCT05523089 - The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults Phase 2
Completed NCT05009251 - Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake N/A
Completed NCT03282240 - Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US Phase 3
Completed NCT00968526 - Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT00971425 - Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1) Phase 3
Completed NCT00968539 - Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT05525494 - Patient Portal Flu Vaccine Reminders (5) N/A
Completed NCT04074928 - Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects Phase 3
Completed NCT04695717 - This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam Phase 3
Completed NCT05012163 - Lottery Incentive Nudges to Increase Influenza Vaccinations N/A
Completed NCT03888989 - Response to Influenza Vaccine During Pregnancy Phase 1
Completed NCT04109222 - Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively Phase 4
Completed NCT02587221 - Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age Phase 3
Completed NCT03453801 - The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection Phase 1
Completed NCT01440387 - A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older Phase 3
Terminated NCT01195779 - Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children Phase 2
Completed NCT03321968 - Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults Phase 3
Completed NCT00972517 - Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children Phase 3
Completed NCT04570904 - Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
Recruiting NCT03331991 - Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel N/A